A common androgen synthesis variant is associated with COVID susceptibility

Authors: Jeffrey M. McManus[1], Navin Sabharwal[1], Peter Bazeley[2] and Nima Sharifi[1,3,4*]

Affiliations:

[1]Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

[2]Center for Clinical Genomics, Genomics Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.

[3]Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.

[4]Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.

*Corresponding author

Email: sharifn@ccf.org

Summary Paragraph

A sex discordance in COVID exists, with males disproportionately affected[1-3]. More broadly, sex differences in infectious and inflammatory processes are well known, with women tending to mount stronger immune responses than men[4,5]. Although there is evidence that sex hormone signaling is immunomodulatory[6-8], including downregulation of immune/inflammatory responses by androgens[9], the existence of numerous other physiologic differences between the sexes leads to great uncertainty in attributing worse infectious disease outcomes in men to androgen signaling. No definitive genetic data exist to support androgen-mediated immune suppression for viral susceptibility, nor for adrenal androgens. Here we show an association between inheritance of the common adrenal-permissive missense-encoding variant *HSD3B1*(1245C), that enables androgen synthesis from adrenal precursors[10], and susceptibility to COVID. The adrenal-permissive *HSD3B1*(1245C) has previously been linked to suppression of inflammation in severe asthma[11]. In analysis of COVID test results from the UK Biobank, we show that in older (≥ 70 years of age) subjects, the adrenal-permissive variant is associated with a greater chance of being COVID-positive. The effect increases with the number of *HSD3B1*(1245C) alleles inherited and is greater in females such that increasing androgen synthesis confers risk approaching males. Our study suggests that a common androgen synthesis variant regulates immune susceptibility to COVID infection as well as potentially other immune and inflammatory processes.

Main Text

Introduction

The COVID-19 pandemic caused by the SARS-CoV-2 virus emerged in late 2019 and in the early months of 2020 quickly became a global health emergency. Recognition that men face higher risks of hospitalization and death from COVID than women[1-3] has spurred research into whether sex hormone signaling plays a role in COVID susceptibility and/or outcomes. Although much of this research has focused on whether androgens regulate viral receptor protein ACE2 and co-receptor TMPRSS2[12-15], it is also known that sex hormone signaling can modulate immune responses[6-8]. Generally speaking, a sex discordance in inflammatory and infectious disease processes[4,5], including COVID, is recognized. However, there is great uncertainty in attributing the difference in outcomes to androgens because there are many other physiologic differences that exist between males and females.

The enzyme 3β-hydroxysteroid dehydrogenase isotype 1 (3βHSD1) catalyzes a critical and rate-limiting step in the pathway to production in peripheral tissues of the potent androgens testosterone and dihydrotestosterone (DHT) from adrenally produced precursors dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S[10]. The adrenal-permissive form of the gene for 3βHSD1, *HSD3B1*(1245C), that was originally linked to faster prostate cancer progression in the face of androgen deprivation therapy (i.e., medical castration) because of adrenally derived androgen synthesis[16-21], has more recently been shown to also affect the response to oral glucocorticoid treatment in patients with severe asthma[11]. The 1245C, or adrenal-permissive allele, encodes a form of the enzyme that is resistant to ubiquitination and degradation, thus leading to increased production of potent androgens from adrenal precursors. By contrast, the 1245A, or

adrenal-restrictive allele, encodes a more rapidly degraded form of the enzyme, leading to less production of potent androgens[22]. A side effect of glucocorticoid treatment is suppression of circulating DHEA and DHEA-S levels[11]. Active androgens (i.e., potent agonists of the androgen receptor) testosterone and DHT are thought to downregulate immune/inflammatory responses[9]. Thus, even in an environment of a decreased adrenal precursor pool brought on by glucocorticoid treatment, the adrenal-permissive 1245C allele still enables sufficient downstream androgen production to reduce airway inflammation in those with severe asthma, whereas patients with the adrenal-restrictive 1245A allele experience less reduction in airway inflammation[11] (**Fig. 1**).

The frequency of the C allele varies enormously across different racial and ethnic groups and is highest among Europeans, particularly in Southern Europe[23,24]. Early in the COVID-19 pandemic, two of the worst outbreaks occurred in Italy and Spain, countries among those with the highest 1245C allele frequencies. This, in conjunction with the evidence from cohorts of severe asthmatics that *HSD3B1* genotype could affect immune responses, led us to ask whether there are links between *HSD3B1* genotype and COVID susceptibility and/or outcomes. Additionally, in both prostate cancer and asthma, the effect of the adrenal-permissive allele becomes evident specifically in contexts of decreased circulating androgen levels due to androgen deprivation therapy in prostate cancer and glucocorticoid treatment in asthma. Circulating androgen levels decline with age[25-27], so as COVID most severely impacts older patients[2,28], this provided further impetus for determining whether a link exists between *HSD3B1* and COVID.

Results

To examine whether COVID susceptibility and *HSD3B1* genotype are associated, we performed regression analyses between presence of a positive COVID test result and genotype in

COVID-tested subjects of the UK Biobank Caucasian cohort; UK Biobank subjects of other races were excluded due to inadequate sample sizes and lower frequency of the 1245C allele. The UK Biobank is a long-term study containing genotyping results and detailed medical information from approximately 500,000 UK residents who were between the ages of 40 and 69 years when recruited to the study in 2006-2010[29]. Current ages range from 50 to 83 with a median age of 70. As of August 3, 2020, COVID test results had been reported for 10,061 Caucasian UK Biobank subjects, 1,148 having tested positive.

We performed logistic regressions and calculated odds ratios including both a regression against the number (0, 1, or 2) of adrenal-permissive *HSD3B1* 1245C alleles and a comparison of homozygous 1245C (CC) genotype to the combined pool of AA and AC genotypes. We analyzed men and women of all ages together as well as men and women separately, and to determine whether there is an association specific to those of advanced age, we further broke these groups down according to age below 70 (the median age of the overall cohort) and age 70 or above. The results (**Table 1, Fig. 2a**) show COVID positivity is associated with CC genotype in subjects of age 70 or above (OR = 1.30, 95% CI = 1.01 – 1.68) and that this association appears to be more pronounced in women (OR = 1.49, 95% CI = 1.02 – 2.16) than in men (OR = 1.20, 95% CI = 0.85 – 1.69).

To test whether the association in subjects of elevated age might be due to selecting a cutoff age that happened to create the strongest result, we systematically varied the lower cutoff age for inclusion in the regression analysis from 50 (i.e., no exclusions due to age) through 80 and calculated the odds ratios and confidence intervals by year of cutoff age. **Figure 3** shows the results for women: for each year of age, the odds ratio and confidence interval for COVID positivity among women of that age or older are shown. Because results similar to our initial cutoff were

obtained over a wide range of cutoff ages, the association in subjects of elevated age is not the result of having selected a specific age. As the cutoff age increases, the odds ratio tends to become larger; at the same time, the confidence interval grows wider as the sample size decreases due to the more restrictive age cutoff (e.g., at a cutoff age of 70, subjects of age 70-83 are included; at a cutoff age of 80, only subjects of age 80-83 are included). Similar results but with lower odds ratios were obtained for men and women together (**Fig. S1a**). For men alone, the shape of the graph is similar, but the lower bound of the confidence interval only reaches 1 for a limited range of cutoff ages above 75 (**Fig. S1b**), suggesting the possibility that older men's COVID positivity associates with CC genotype in a way similar to older women's but less strongly.

We additionally observed that when looking at all genotypes together, men had a higher positive test rate than women (men: 12.3% positive, 95% CI = 11.4% - 13.2%; women: 10.5% positive, 95% CI = 9.7% - 11.3%). However, women with the CC genotype had a similar positive rate to the overall male positive rate (12.5%, 95% CI = 9.7% - 15.3%). Specifically, in women at least 70 years of age, the positive rate appeared to increase in a stepwise fashion with the number of C alleles: 0 C alleles, 7.9% (95% CI = 6.4% - 9.4%); 1 C allele, 9.2% (95% CI = 7.5% - 10.9%); 2 C alleles, 12.2% (95% CI = 8.5% - 15.9%).

Having found that *HSD3B1* genotype is associated with the rate of COVID positivity, we next performed the same analysis but on the entire UK Biobank Caucasian cohort rather than just those who had COVID test results. We compared those who had tested positive for COVID to all other members of the cohort, including analyses with the same breakdowns by sex and age. The results (**Table S1, Fig. 2b**) are very similar to the results when analyzing only those who were COVID-tested. Again, there is an association between COVID positivity and CC genotype in subjects of age 70 or above (OR = 1.30, 95% CI = 1.03 – 1.65), and this association appears to be

more pronounced in women (OR = 1.55, 95% CI 1.09 – 2.20) than in men (OR = 1.14, 95% CI 0.83 – 1.57).

We next analyzed the UK Biobank's death records to test for associations between COVID as a cause of death and *HSD3B1* genotype. We again analyzed the entire Caucasian cohort, men and women separately, and these same groups restricted to those at least 70 years of age. Analyses limited to those under 70 years of age were not included because the number of deaths was very small among those under 70. Although no associations reached the p = 0.05 level (**Table S2**), we did observe a trend toward higher risk of COVID death in women of CC genotype but not in men, and the strongest trend was in women at least 70 years of age with the CC genotype (OR 1.60, 95% CI 0.92 – 2.77). It should be noted that the set of COVID deaths only partly overlaps the set of COVID-positive cases from the previous analyses: of 325 total COVID deaths, 200 were people who had tested positive for COVID, 110 were people who had no COVID test results reported, and 15 were people who had only negative COVID test results reported.

We also analyzed associations between all-cause mortality and *HSD3B1* genotype among only those subjects of the UK Biobank Caucasian cohort with positive COVID test results (**Table S3**). This analysis contained the smallest sample sizes, and again no associations reached the p = 0.05 level. However, it was striking that, as with all the previous analyses of both COVID susceptibility and COVID mortality, the largest association was observed in women at least 70 years of age with the CC genotype (OR 1.59, 95% CI 0.74 – 3.41).

Discussion

We have demonstrated that, in the UK Biobank Caucasian cohort, there is an association between possessing two copies of the adrenal-permissive *HSD3B1* 1245C allele and testing

positive for COVID-19 in subjects age 70 or older, and the size of the effect becomes larger when looking specifically at women age 70 or older. This association exists whether comparing those subjects who tested positive to those who tested negative (**Table 1, Fig. 2A**) or comparing those subjects who tested positive to all other members of the population (**Table S1, Fig. 2B**). This association in older women is not an artifact of having selected a specific cutoff age, but rather is present over a wide range of cutoff ages (**Figure 3**). A similar but weaker effect may be present in older men with the CC genotype (**Figure S1**).

It may be seen as surprising that results were so similar when comparing COVID-positive subjects to COVID-negative subjects as when comparing positive subjects to all other subjects, as one might assume that the pool of non-tested subjects would contain both COVID-positive and -negative subjects, and would therefore fall between the COVID-positive pool and the COVID-negative pool. However, considering that there is a substantial false-negative rate in COVID testing[30], and that someone who has been tested for COVID would *a priori* be more likely to have been infected with COVID than a random member of the population, this similarity becomes less surprising.

Previously reported phenotypic associations with adrenal-restrictive vs. adrenal-permissive *HSD3B1* genotype, in both prostate cancer and asthma, occur in contexts of reduced circulating androgen levels. Circulating androgen levels, including levels of the adrenally produced precursor DHEA that is a 3βHSD1 substrate in the pathway to potent androgen production, decrease with increasing age in both sexes, which is in line with the association we observed specifically in subjects of advanced age. Furthermore, in men, the pool of gonadally produced androgens is vastly larger than in women; therefore, the relative contribution of adrenally produced androgens is greater in women, in line with the association with adrenal-permissive androgen synthesis being

stronger in women. As COVID outcomes are by far the worst in elderly patients, the existence of a germline steroid-metabolizing enzyme variant that makes older people more susceptible to COVID is of physiologic and potentially pharmacologic importance. Intriguingly, whereas the overall higher positive rate we observed in men compared to women aligns with the well-known existence of greater rates of severe COVID and COVID death among men, when looking specifically at women of CC genotype, the positive rate reached the overall positive rate in men, genetically supporting the androgen association.

The results on COVID mortality in this cohort are based on relatively small sample sizes and must be considered preliminary, but it is striking that, as with both methods of analyzing association with COVID positivity (**Table 1** and **Table S1**), the largest associations with COVID mortality among all UK Biobank Caucasian subjects (**Table S2**) and with mortality among COVID-positive UK Biobank Caucasian subjects (**Table S3**) were in women of CC genotype age 70 or older. If these associations are real, an association with COVID mortality among women in general could be simply a consequence of the association with COVID susceptibility, whereas an association with mortality among COVID-positive women would imply that the CC genotype also leads to worse outcomes among infected women. It should, however, be noted that the latter association has the smallest sample size and weakest statistical support.

Although our interrogation of these associations was originally inspired in part by severe COVID outbreaks in countries like Italy and Spain whose populations have high germline frequencies of the adrenal-permissive 1245C allele, it is also the case that higher rates of COVID infection and death have occurred in the United States among people of African descent[31,32], a population with much lower 1245C allele frequencies than Caucasians (C allele frequencies in the UK Biobank: African 0.085, Caucasian 0.323, consistent with results reported elsewhere[23]).

Therefore, although possessing the adrenal-permissive allele might affect an individual person's COVID susceptibility, many other genetic and socioeconomic factors must be considered and are confounding across different races and ethnicities.

It was recently shown in a large, randomized trial that treatment with the glucocorticoid dexamethasone strongly reduced mortality in COVID patients on ventilation but not in patients receiving no respiratory support[33]. Taken together with the findings we report here and our previous finding that *HSD3B1* genotype affects response to glucocorticoid treatment in asthma with the adrenal-permissive 1245C allele associated with reduced airway inflammation[11], this raises the question of whether *HSD3B1* genotype could affect response to dexamethasone in COVID patients. The differential effects of dexamethasone in patients who were or were not receiving respiratory support also highlights how the results of steroid-induced immune suppression could be context-dependent: immune suppression could make it harder to ward off an initial infection, but could be beneficial in a patient with an advanced infection and out-of-control inflammatory response.

All the results reported here require validation from an independent cohort. If this validation is forthcoming, it would be an important finding in both the field of COVID research as well as in the broader area of the role of sex hormones in immune responses. Importantly, the existence of a differential immune response based on differential androgen metabolism occurring specifically within one sex (i.e., women) could help shed light on the role of androgens in immune responses in general. Comparisons between men (higher androgen levels) and women (lower androgen levels) are confounded by numerous other physiologic differences between the sexes; in a comparison between women with adrenal-permissive and women with adrenal-restrictive androgen synthesis, these confounding factors are absent. The mechanisms by which inherited

adrenal androgen metabolism by way of *HSD3B1* genotype affects immune responses are subjects for future study.

References

1 Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology* **20**, 442-447, doi:10.1038/s41577-020-0348-8 (2020).

2 Palaiodimos, L. *et al.* Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism* **108**, 154262-154262, doi:10.1016/j.metabol.2020.154262 (2020).

3 Michelozzi, P. *et al.* Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020. *Eurosurveillance* **25**, 2000620, doi:doi:https://doi.org/10.2807/1560-7917.ES.2020.25.19.2000620 (2020).

4 Fischer, J., Jung, N., Robinson, N. & Lehmann, C. Sex differences in immune responses to infectious diseases. *Infection* **43**, 399-403, doi:10.1007/s15010-015-0791-9 (2015).

5 Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nature reviews. Immunology* **16**, 626-638, doi:10.1038/nri.2016.90 (2016).

6 Bouman, A., Heineman, M. J. & Faas, M. M. Sex hormones and the immune response in humans. *Human Reproduction Update* **11**, 411-423, doi:10.1093/humupd/dmi008 (2005).

7 Foo, Y. Z., Nakagawa, S., Rhodes, G. & Simmons, L. W. The effects of sex hormones on immune function: a meta-analysis. *Biological Reviews* **92**, 551-571, doi:10.1111/brv.12243 (2017).

8 Taneja, V. Sex Hormones Determine Immune Response. *Frontiers in Immunology* **9**, doi:10.3389/fimmu.2018.01931 (2018).

9 Gubbels Bupp, M. R. & Jorgensen, T. N. Androgen-Induced Immunosuppression. *Frontiers in Immunology* **9**, doi:10.3389/fimmu.2018.00794 (2018).

10 Naelitz, B. D. & Sharifi, N. Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics. *Trends Endocrinol Metab*, doi:10.1016/j.tem.2020.05.006 (2020).

11 Zein, J. *et al.* HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma. *Proceedings of the National Academy of Sciences* **117**, 2187-2193, doi:10.1073/pnas.1918819117 (2020).

12 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278, doi:https://doi.org/10.1016/j.cell.2020.02.052 (2020).

13 Mjaess, G., Karam, A., Aoun, F., Albisinni, S. & Roumeguère, T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. *Progrès en Urologie*, doi:https://doi.org/10.1016/j.purol.2020.05.007 (2020).

14 Sharifi, N. & Ryan, C. J. Androgen hazards with COVID-19. *Endocrine-related cancer* **27**, E1-e3, doi:10.1530/erc-20-0133 (2020).

15 Song, H., Seddighzadeh, B., Cooperberg, M. R. & Huang, F. W. Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. *Eur Urol* **78**, 296-298, doi:10.1016/j.eururo.2020.04.065 (2020).

16 Hearn, J. W. D. *et al.* HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. *Lancet Oncol* **17**, 1435-1444, doi:10.1016/S1470-2045(16)30227-3 (2016).

17 Agarwal, N. *et al.* Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. *JAMA Oncol*, doi:10.1001/jamaoncol.2017.0147 (2017).

18 Shiota, M. *et al.* Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. *JAMA Netw Open* **2**, e190115, doi:10.1001/jamanetworkopen.2019.0115 (2019).

19 Garcia Gil, S., Ramos Rodriguez, R., Plata Bello, A., Nazco Casariego, G.J., Garcia Marrero, R., Cruz Jurado, J., Batista Lopez, J.N., Gonzalez Garcia, J., Gutierrez Nicolas, F. in *European Society of Oncology Pharmacy* (Nantes, France, 2018).

20 Hearn, J. W. D. *et al.* Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. *JAMA Oncol* **4**, 558-562, doi:10.1001/jamaoncol.2017.3164 (2018).

21 Hearn, J. W. D. *et al.* HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. *JAMA Oncology* **6**, e196496-e196496, doi:10.1001/jamaoncol.2019.6496 (2020).

22 Chang, K. H. *et al.* A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. *Cell* **154**, 1074-1084, doi:10.1016/j.cell.2013.07.029 (2013).

23 Sabharwal, N. & Sharifi, N. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. *Endocrinology* **160**, 2180-2188, doi:10.1210/en.2019-00366 (2019).

24 *IGSR: The International Genome Sample Resource. Genome browsers.* <https://www.internationalgenome.org/1000-genomes-browsers/> (Accessed 11 August 2020)

25 Laughlin, G. A. & Barrett-Connor, E. Sexual Dimorphism in the Influence of Advanced Aging on Adrenal Hormone Levels: The Rancho Bernardo Study1. *The Journal of Clinical Endocrinology & Metabolism* **85**, 3561-3568, doi:10.1210/jcem.85.10.6861 (2000).

26 Muller, M., den Tonkelaar, I., Thijssen, J. H., Grobbee, D. E. & van der Schouw, Y. T. Endogenous sex hormones in men aged 40-80 years. *European journal of endocrinology* **149**, 583-589, doi:10.1530/eje.0.1490583 (2003).

27 Horstman, A. M., Dillon, E. L., Urban, R. J. & Sheffield-Moore, M. The Role of Androgens and Estrogens on Healthy Aging and Longevity. *The Journals of Gerontology: Series A* **67**, 1140-1152, doi:10.1093/gerona/gls068 (2012).

28 Du, R.-H. *et al.* Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *The European respiratory journal* **55**, 2000524, doi:10.1183/13993003.00524-2020 (2020).

29 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).

30 Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of internal medicine*, M20-1495, doi:10.7326/M20-1495 (2020).

31 Webb Hooper, M., Nápoles, A. M. & Pérez-Stable, E. J. COVID-19 and Racial/Ethnic Disparities. *JAMA* **323**, 2466-2467, doi:10.1001/jama.2020.8598 (2020).

32 Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *New Engl J Med* **382**, 2534-2543, doi:10.1056/NEJMsa2011686 (2020).

33 Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*, doi:10.1056/NEJMoa2021436 (2020).

Tables

Table 1. Odds ratios for COVID positivity by *HSD3B1* genotype among COVID-tested members of the UK Biobank Caucasian cohort.

Group	N (cases; controls)	regression against number of C alleles: odds ratio (95% confidence interval)	regression against number of C alleles: p-value	comparison of CC genotype vs. other (AA or AC) genotypes: odds ratio (95% confidence interval)	comparison of CC genotype vs. other (AA or AC) genotypes: p-value
both sexes all ages	10,061 (1148; 8913)	1.05 (0.96 – 1.15)	0.322	1.19 (0.98 – 1.44)	0.079
male all ages	5042 (621; 4421)	0.99 (0.87 – 1.12)	0.859	1.13 (0.86 – 1.48)	0.397
female all ages	5019 (527; 4492)	1.12 (0.98 – 1.28)	0.106	1.26 (0.96 – 1.65)	0.102
both sexes age < 70	4111 (536; 3575)	0.99 (0.86 – 1.14)	0.936	1.03 (0.76 – 1.40)	0.836
age ≥ 70	5950 (612; 5338)	1.08 (0.96 – 1.23)	0.206	1.30 (1.01 – 1.68)	0.038
male age < 70	1814 (252; 1562)	1.00 (0.81 – 1.23)	0.999	1.03 (0.65 – 1.63)	0.900
age ≥ 70	3228 (369; 2859)	0.98 (0.83 – 1.16)	0.832	1.20 (0.85 – 1.69)	0.297
female age < 70	2297 (284; 2013)	0.99 (0.82 – 1.20)	0.926	1.04 (0.69 – 1.56)	0.851
age ≥ 70	2722 (243; 2479)	1.24 (1.03 – 1.50)	0.025	1.49 (1.02 – 2.16)	0.037

Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to one sex).

Figures



Figure 1. Adrenal-permissive *HSD3B1* genotype leads to greater androgen synthesis and immune suppression. Depending on genotype, *HSD3B1* codes for an enzyme 3βHSD1 that is either readily ubiquitinated and degraded (adrenal-restrictive form, left) or is resistant to ubiquitination and degradation (adrenal-permissive form, right) and as a result accumulates at higher levels in cells. The higher levels of the adrenal-permissive enzyme enable greater conversion of DHEA to downstream potent androgens at sufficient levels to suppress immune responses, whereas these levels are not reached with the adrenal-restrictive form. Created with BioRender.com.



Figure 2. Older subjects, particularly older women, who are homozygous for the adrenal-permissive *HSD3B1*(1245C) allele have heightened COVID positivity. Odds ratios and 95% confidence intervals for COVID positivity in subjects of CC genotype vs. other (AA or AC) genotypes in different age and sex breakdowns of the UK Biobank Caucasian cohort. **(A)** Subjects who tested positive for COVID vs. subjects who tested negative for COVID. For numbers of cases and controls in each group, see **Table 1**. **(B)** COVID-positive subjects vs. all other members of cohort. For numbers of cases and controls in each group, see **Table S1**. Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to one sex).



Figure 3. CC genotype associates with higher COVID positivity in older women regardless of the lower cutoff age for inclusion in the analysis. Odds ratios (thick line) and 95% confidence intervals (thin lines) for being COVID-positive in Caucasian women at least [cutoff age] years old with CC genotype vs. other genotypes (AA or AC), by cutoff age. For each year of age, the odds ratio and confidence interval in COVID-tested women that age or older were calculated. Note that the result at a lower cutoff age of 70 is the same as the "female, age ≥ 70" result in the right-hand side of **Table 1**.

Methods

Analysis was performed on subjects from the UK Biobank, a long-term study tracking medical information of over 500,000 genotyped individuals. Genotyping was performed using the UK BiLEVE Axiom Array or UK Biobank Axiom Array by Applied Biosystems. Additional SNPs were imputed with the IMPUTE4 program using the Haplotype Reference Consortium, UK10K, and 1000 Genomes phase 3 panels as reference panels. Rs1047303 (i.e., *HSD3B1*(1245A/C)) was imputed with high accuracy (information score > 0.99).

Population structure and ancestry were assessed via principal component analysis on SNP data, and outliers were excluded. Final sample sizes for different ethnicities after quality control were 384,810 Caucasian, 7224 African, 7193 South Asian, and 1409 Chinese. The sample sizes for subjects with COVID test results available as of August 3, 2020, by ethnicity, were 10,061 Caucasian, 300 African, 253 South Asian, and 31 Chinese. Due to inadequate sample sizes as well as lower *HSD3B1*(1245C) frequencies of other ethnicities (1245C frequencies in overall cohort by ethnicity: 0.323 Caucasian, 0.085 African, 0.193 South Asian, 0.074 Chinese), analyses reported in this study were limited to subjects of Caucasian ethnicity.

For analysis of mortality with COVID as a cause of death, death records from the UK Biobank were downloaded, and subjects with ICD10 codes U07.1 (i.e., laboratory-confirmed COVID) or U07.2 (i.e., clinically diagnosed COVID without laboratory confirmation) in a cause of death field were identified. For analysis of mortality among COVID-positive subjects, death records were cross referenced against COVID test results and subjects who died after having tested positive for COVID were identified.

Analyses were performed using R under RStudio. This study was approved by the NHS National Research Ethics Committee (REC ref 16/NW/0274) through the generic ethical approval for UK Biobank studies (approved UK Biobank application #44578).

Data and materials availability: Data are regulated by UK Biobank's policies on access.

Acknowledgments:

Funding: This work was supported in part with grants from the National Cancer Institute (R01CA172382, R01CA190289, and R01CA236780) and the Prostate Cancer Foundation (to NS).

Author contributions: Jeffrey M. McManus: conceptualization, methodology, investigation, writing – original draft, visualization; Navin Sabharwal: methodology, investigation, data curation; Peter Bazeley: methodology, data curation; Nima Sharifi: conceptualization, writing – review & editing, supervision, funding acquisition

Competing interests: Cleveland Clinic has a patent on *HSD3B1* in prostate cancer.

Extended Data

Table S1. Odds ratios for COVID positivity (COVID-positive vs. all other members of cohort) by *HSD3B1* genotype in the UK Biobank Caucasian cohort.

		regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
Group	**n (cases; controls)**	**odds ratio (95% confidence interval)**	**p-value**	**odds ratio (95% confidence interval)**	**p-value**
both sexes all ages	384,810 (1148; 383,667)	1.03 (0.94 – 1.12)	0.535	1.14 (0.95 – 1.36)	0.156
male all ages	178,118 (621; 177,497)	0.97 (0.86 – 1.10)	0.667	1.04 (0.81 – 1.34)	0.748
female all ages	206,692 (527; 206,165)	1.10 (0.96 – 1.24)	0.161	1.26 (0.97 – 1.63)	0.080
both sexes age < 70	187,714 (536; 187,178)	0.99 (0.87 – 1.12)	0.854	0.96 (0.73 – 1.28)	0.801
age ≥ 70	197,096 (612; 196,484)	1.07 (0.95 – 1.20)	0.295	1.30 (1.03 – 1.65)	0.029
male age < 70	83,980 (252; 83,728)	0.97 (0.81 – 1.17)	0.778	0.90 (0.59 – 1.37)	0.623
age ≥ 70	94,138 (369; 93,769)	0.98 (0.84 – 1.14)	0.762	1.14 (0.83 – 1.57)	0.408
female age < 70	103,734 (284; 103,450)	1.00 (0.84 – 1.19)	0.988	1.02 (0.70 – 1.49)	0.909
age ≥ 70	102,958 (243; 102,715)	1.21 (1.01 – 1.46)	0.040	1.55 (1.09 – 2.20)	0.014

Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to one sex).

Table S2. Odds ratios for mortality with COVID as a cause of death by *HSD3B1* genotype in the UK Biobank Caucasian cohort.

		regression against number of C alleles		comparison of CC genotype vs. other (AA or AC) genotypes	
Group	**n (cases; controls)**	**odds ratio (95% confidence interval)**	**p-value**	**odds ratio (95% confidence interval)**	**p-value**
both sexes all ages	384,810 (325; 384,485)	1.01 (0.85 – 1.19)	0.936	1.14 (0.82 – 1.61)	0.435
male all ages	178,118 (212; 177,906)	0.94 (0.76 – 1.15)	0.525	0.95 (0.61 – 1.49)	0.829
female all ages	206,692 (113; 206,579)	1.15 (0.88 – 1.51)	0.315	1.53 (0.91 – 2.56)	0.109
both sexes age ≥ 70	197,096 (281; 196,815)	0.97 (0.81 – 1.16)	0.743	1.19 (0.83 – 1.71)	0.339
male age ≥ 70	94,138 (185; 93,953)	0.90 (0.72 – 1.12)	0.335	0.99 (0.62 – 1.60)	0.974
female age ≥ 70	102,958 (96; 102,862)	1.12 (0.84 – 1.51)	0.439	1.60 (0.92 – 2.77)	0.096

Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to one sex).

Table S3. Odds ratios for all-cause mortality by *HSD3B1* genotype among subjects who tested COVID+ in the UK Biobank Caucasian cohort.

Group	n (cases; controls)	regression against number of C alleles: odds ratio (95% confidence interval)	regression against number of C alleles: p-value	comparison of CC genotype vs. other (AA or AC) genotypes: odds ratio (95% confidence interval)	comparison of CC genotype vs. other (AA or AC) genotypes: p-value
both sexes all ages	1107 (220; 887)	1.03 (0.82 – 1.29)	0.786	1.10 (0.70 – 1.75)	0.674
male all ages	598 (147; 451)	0.97 (0.73 – 1.30)	0.845	0.92 (0.50 – 1.71)	0.802
female all ages	509 (73; 436)	1.13 (0.78 – 1.64)	0.508	1.38 (0.69 – 2.79)	0.365
both sexes age ≥ 70	596 (183; 413)	1.05 (0.82 – 1.35)	0.696	1.22 (0.73 – 2.02)	0.447
male age ≥ 70	361 (123; 238)	0.95 (0.69 – 1.30)	0.730	0.98 (0.50 – 1.93)	0.957
female age ≥ 70	235 (60; 175)	1.24 (0.83 – 1.87)	0.296	1.59 (0.74 – 3.41)	0.239

Results were adjusted for sex, age, and BMI (regressions including both sexes) or for age and BMI (regressions limited to one sex). Inclusion in analysis was restricted to subjects who tested COVID+ prior to the most recent reported death (June 28, 2020) at the time analyses were performed.



Figure S1. Effect of lower cutoff age on associations between CC genotype and COVID positivity for Caucasians of both sexes or of male sex. Odds ratios (thick line) and 95% confidence intervals (thin lines) for being COVID-positive in men and women together **(A)** or men **(B)** at least [cutoff age] years old with CC genotype vs. AA or AC genotype, by cutoff age. For each year of age, the odds ratio and confidence interval in COVID-tested subjects that age or older were calculated. Note that the results at a cutoff age of 70 are the same as the "both sexes, age ≥ 70" **(A)** or "male, age ≥ 70" **(B)** results in the right-hand side of **Table 1**.